Organization
Abbott GmbH & Co KG, Wiesbaden, Germany
3 abstracts
Abstract
ADALIMUMAB REDUCES INFLAMMATION IN THE SACROILIAC JOINTS OF PATIENTS WITH ACTIVE SPONDYLOARTHRITIS WITHOUT RADIOGRAPHIC SACROILIITIS — RESULTS OF A PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL THROUGH 52 WEEKS Org: Abbott Laboratories, Abbott GmbH & Co KG, Wiesbaden, Germany, German Rheumatism Research Centre, Pathophysiology of Rheumatic Inflammation, Berlin, Germany, Centre of Rheumatology, Herne,
Abstract
ADALIMUMAB IS EFFECTIVE AND WELL-TOLERATED IN TREATING ANKYLOSING SPONDYLITIS (AS) IN REAL-LIFE CLINICAL PRACTICE: PRELIMINARY RESULTS OF THE RHAPSODY TRIALOrg: Rheumatology, Society of Patients with Rheumatism, Cracow, Poland, Charité University Hospital, Berlin Heals, Germany, CHU de Henri-Mondor,
Abstract
ADALIMUMAB (HUMIRA®) THERAPY FOR PATIENTS WITH RHEUMATOID ARTHRITIS (RA): IMPACT OF BASELINE CHARACTERISTICS ON THERAPEUTIC SUCCESS FROM A GERMAN NON-INTERVENTIONAL STUDY Org: Abbott GmbH & Co KG, Wiesbaden, Germany,